Lina Grymchan, PA-C

Lina Grymchan practices at Cedars-Sinai Medical Care Foundation in Beverly Hills, California.

Lina Grymchan's NPI, 1184189201, was assigned on February 2, 2019. Lina Grymchan holds California license PA56447.

Lina Grymchan's primary practice is Cedars-Sinai Medical Care Foundation, at 8501 Wilshire Blvd, Beverly Hills, CA 90211 in Los Angeles County. The practice phone is (310) 385-3200.

Lina Grymchan's primary practice is Cedars-Sinai Medical Care Foundation in Beverly Hills, California. Lina Grymchan is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Lina Grymchan to 5 more group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Lina Grymchan practices, 6 sites in all. Vendor and product names are available with a free account.

Physician assistant is Lina Grymchan's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Lina Grymchan is licensed in California.

Dmand AI lists acute skin infection, chest wall injury, conjunctivitis, ear eustachian tube disorders, fibromyalgia and chronic pain, hives, lower back pain and minor injury to a limb among the conditions Lina Grymchan treats.

CMS data shows 357 Medicare services from Lina Grymchan across 10 procedure codes in 2024, for 173 Medicare patients. Medicare paid $56,218 for them. Every service was in an office.

CMS counts 173 Medicare patients who saw Lina Grymchan in 2024. The largest group is 65 to 74, with 93 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 46% are also on Medicaid. Their average risk score is 1.21, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Lina Grymchan's median patient age at 61, with 67% women.

In 2024, Lina Grymchan wrote 153 Medicare Part D claims for 105 patients. 92% of them were for generic drugs. CMS names the drug for 61 of them, across 3 drugs with 11 or more claims each, at $761 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Lina Grymchan for performance year 2024, reported as part of a group. Lina Grymchan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Lina Grymchan from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. Galderma Laboratories, L.P. paid the most, $281.